Table 2. Baseline Characteristics of 152 Patients.
| Variable | Value | ||
|---|---|---|---|
| Sex | |||
| Male | 125 (82.2) | ||
| Female | 27 (17.8) | ||
| Age, year* | 61.4 ± 10.1 | ||
| Cause of chronic liver disease | |||
| HBV | 103 (67.8) | ||
| HCV | 26 (17.1) | ||
| HBV + HCV | 5 (3.3) | ||
| Non-viral | 18 (11.8) | ||
| History of surgical HCC treatment | 4 (2.6) | ||
| History of other malignancies | 11 (7.2) | ||
| Child-Pugh score | |||
| A5 | 105 (69.1) | ||
| A6 | 38 (25.0) | ||
| B7 | 9 (5.9) | ||
| ECOG performance status | |||
| 0 | 114 (75.0) | ||
| 1 | 38 (25.0) | ||
| Maximum tumor diameter, cm† | 3.6 ± 2.2; 3.0 (2.2–4.5) | ||
| Sum of target lesion diameters, cm† | 5.5 ± 7.0; 3.8 (2.6–5.9) | ||
| Number of tumors | |||
| Single, cm | 84 (55.3) | ||
| < 2 | 18 (11.8) | ||
| 2–5 | 51 (33.6) | ||
| > 5 | 15 (9.9) | ||
| Multiple | 68 (44.7) | ||
| Within Milan criteria | 34 (22.4) | ||
| Beyond Milan criteria | 34 (22.4) | ||
| Bilobar disease | 43 (28.3) | ||
| BCLC stage‡ | |||
| 0 | 11 (7.2) | ||
| A | 77 (50.7) | ||
| B | 26 (17.1) | ||
| C | 38 (25.0) | ||
| Okuda stage | |||
| I | 135 (88.8) | ||
| II | 17 (11.2) | ||
| Modified UICC stage | |||
| I | 18 (11.8) | ||
| II | 78 (51.3) | ||
| III | 56 (36.8) | ||
| Alpha fetoprotein level, ng/mL† | 1100.7 ± 4573.7; 17.3 (6.1–159.4) |
||
| ≤ 20 | 78 (51.3) | ||
| > 20, ≤ 400 | 48 (31.6) | ||
| > 400 | 26 (17.1) | ||
Values are number of patients and lesions with the percentage in parentheses unless specified otherwise. *Values are mean ± SD, †Values are mean ± SD; and median with interquartile range in parentheses, ‡BCLC stage A included all the patients with single tumor regardless of its size. BCLC = Barcelona Clinic Liver Cancer, HBV = hepatitis B virus, HCV = hepatitis C virus, ECOG = Eastern Cooperative Oncology Group, HCC = hepatocellular carcinoma, SD = standard deviation, UICC = Union for International Cancer Control